Based on the assumption that SGLT2 was responsible for the bulk of glucose reabsorption, the pharmaceutical industry in Japan, USA and Europe invented SGLT2 inhibitors to treat type 2 diabetes. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.